CareDx Inc (CDNA) Cotización

CareDx Reports Third Quarter 2023 Results
BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today reported financial results for the third quarter ended September 30, 2023.

Third Quarter 2023 Highlights

Reported revenue of $67.2 million, an increase of 7% over the second quarter of 2023, excluding approximately $7.8 million related to Medicare claims billing that were held over from the first quarter of 2023 and recognized in second quarter 2023 revenue.
Grew Testing Services patient results to 38,400, an increase of 2% compared to the second quarter of 2023.
Achieved revenue of $9.9 million for Digital Solutions and $9.5 million for Products, representing year-over-year growth of 33% for both businesses.
Achieved the fourth consecutive quarter of collections at over 100% of revenue for Testing Services; collected over $22 million in incremental cash in the past four quarters.
Maintained a strong balance sheet, with $268.2 million in cash and cash equivalents, and marketable securities, with no debt.
Received Medicare coverage for HeartCare™ and AlloSure® Lung.
Raised revenue guidance to $274 to $278 million for the full year 2023.
SEC has concluded its inquiry and does not intend to recommend an enforcement action against the Company.
“CareDx continues to be well-placed in the transplant market. We are pleased to see a baseline being set in the Testing Services business in Q3 as patient testing volumes appear to have stabilized,” said Alex Johnson, President of Patient and Testing Services, and member of the Office of the CEO at CareDx. “We remain committed to bringing high impact innovation to the transplant clinic, while accelerating our path back to profitability.”

Third Quarter 2023 Financial Results

Revenue for the three months ended September 30, 2023, was $67.2 million, a decrease of 15% compared with $79.4 million in the third quarter of 2022, and an increase of 7% compared with $62.5 million in the second quarter of 2023, excluding approximately $7.8 million related to Medicare claims billing that were held over from the first quarter of 2023 and recognized in second quarter 2023 revenue. Testing services revenue for the quarter was $47.8 million, compared with $64.8 million in the same period in 2022.

Approximately 38,400 AlloSure® and AlloMap® patient results were provided in the quarter, representing a decrease of 18% as compared to the same quarter a year ago, and an increase of 2% compared to the second quarter of 2023.

For the third quarter of 2023, net loss was $23.5 million, compared to a net loss of $16.9 million in the same period of 2022. Basic and diluted net loss per share in the third quarter of 2023 was $0.43, compared to basic and diluted net loss per share of $0.32 in the third quarter of 2022.

Non-GAAP net loss was $9.6 million in the third quarter of 2023, compared to a non-GAAP net loss of $3.4 million in the third quarter of 2022. Basic and diluted non-GAAP net loss per share was $0.18 in the third quarter of 2023, compared to a basic and diluted non-GAAP net loss per share of $0.06 in the third quarter of 2022.

Adjusted EBITDA for the third quarter of 2023 was a loss of $10.9 million, compared to an adjusted EBITDA loss of $2.5 million in the third quarter of 2022.

Cash and cash equivalents and marketable securities were $268.2 million as of September 30, 2023.

2023 Guidance

For the full year 2023, CareDx expects revenue to be in the range of $274 to $278 million.

About CareDx – The Transplant Company™

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Forward-Looking Statements

This press release includes forward-looking statements, including statements regarding CareDx’s 2023 revenue expectations and the company’s path towards growth. All statements other than statements of historical fact contained in this press release, including statements regarding the future financial position of CareDx, including financial expectations, business strategy and plans and objectives for future operations, are forward-looking statements.

Cathy Woods is

Anybody playing ? CDNA!!!

Float = 17.25M

Profit/Loss = $ -39.47M

CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announces that CMS released the 2018 Clinical Laboratory Fee Schedule confirming that the AlloMap reimbursement rate will be increased to $3,240.


The Center for Medicare and Medicaid Services (CMS) released the final 2018 Clinical Laboratory Fee Schedule (CLFS) today, re-affirming the preliminary rate for AlloMap of $3,240, an increase of 14% compared with the 2017 CMS CLFS rate of $2,840.75. The higher 2018 reimbursement rate for AlloMap was due in part to effective claims management, which increased the weighted median of commercial reimbursement. This data was shared with CMS as required by regulations associated with the Protecting Access to Medicare Act of 2014 (PAMA). The effective date of the increase is January 1, 2018.

“The implementation of PAMA by CMS provides a refreshing predictability to the reimbursement of diagnostic tests,” said Sasha King, Chief Commercial Officer at CareDx. “The updated rate highlights the value AlloMap brings to heart transplant patients.”

About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure™ for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA testing.

For more information, please visit: www.CareDx.com.

CDNA

im n this looks good next qtr. should hit 10 a share

Here we go!!!

* * $CDNA Video Chart 09-26-17 * *

Link to Video - click here to watch the technical chart video

* * $CDNA Video Chart 08-24-17 * *

Link to Video - click here to watch the technical chart video

Guess this news was bigger than I thought.. damnn

Guess we'll have to all watch out for the icehole in fantasyland then... All jokes aside this is going up.

I think the spikes up were instead smarter than average shorts covering at the bottom. Then those that bought too high initially then took the opportunity to get out once the chart popped up.

The longs did not want to wait anymore, the position's unrealized loss on paper weighed in on them for too long and they natually impatiently sold it to get rid of the position. They don't care they sold at the bottom and it was going to recover later, they just wanted relief from the position now.

I do not see any pre planned or concerted pump and dump effort suggested here, no any risky perceptions of thin ice. I know my charting isn't made up of that nor does it include any of those things posed.

* * $CDNA Video Chart 07-26-17 * *

Link to Video - click here to watch the technical chart video

CDNA buy 1.5116

CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions
CareDx, Inc. is dedicated to improving the lives of organ transplant patients through noninvasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx strives to stay at the forefront of organ transplant surveillance solutions.
http://www.caredxinc.com









normal chart




log chart